Åbn hovedmenuen

Ændringer

5 bytes tilføjet, for 4 år siden
m
link
 
== Forskning ==
Calmette-vaccinen har sine begrænsninger, og der forskes stadig i at udvikle nye TB-vacciner. <ref name=VacRes2011> {{cite journal|last=Martín Montañés|first=C|coauthors=Gicquel, B|title=New tuberculosis vaccines.|journal=Enfermedades infecciosas y microbiologia clinica|date=2011 Mar|volume=29 Suppl 1|pages=57–62|pmid=21420568|doi=10.1016/S0213-005X(11)70019-2}} </ref> Flere potentielle kandidater er nu i [[kliniskeKlinisk forsøgundersøgelse|fase I og II kliniske forsøg]]. <ref name=VacRes2011/> To hovedstrategier forsøger at forbedre de eksisterende vacciners effektivitet. Det ene tilføjer en subenhedsvaccine til calmette-vaccinen. Den anden strategi prøver at skaber nye og bedre levende vacciner. <ref name=VacRes2011/> [[MVA85A]] er et eksempel på en subenhedsvaccine, der er i forsøgsstadiet i Sydafrika. MVA85A er baseret på en genetisk modificeret [[vaccinia]]-virus. <ref name=Ibanga_2006> {{cite journal |author=Ibanga H, Brookes R, Hill P, Owiafe P, Fletcher H, Lienhardt C, Hill A, Adegbola R, McShane H |title=Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design |journal=Lancet Infect Dis |volume=6 |issue=8|pages=522–8 |year=2006 |doi= 10.1016/S1473-3099(06)70552-7| pmid = 16870530}} </ref> Det håbes, at vaccination kan spille en stor rolle i behandlingen af latent og aktiv TB. <ref> {{cite journal|author=Kaufmann SH|title=Future vaccination strategies against tuberculosis: Thinking outside the box|journal=Immunity|year=2010|volume=33|pages=567–77|pmid = 21029966|doi=10.1016/j.immuni.2010.09.015|issue=4}} </ref>
 
For at fremme yderligere opdagelser har forskere og politiske beslutningstagere udviklet nye økonomiske modeller for udvikling af vacciner, bl.a. priser, skatteincitamenter og [[advance market commitments|AMC]]. <ref> {{cite journal|author=Webber D, Kremer M|url=http://www.who.int/bulletin/archives/79(8)735.pdf |title=Stimulating Industrial R&D for Neglected Infectious Diseases: Economic Perspectives |journal=Bulletin of the World Health Organization|volume=79|issue=8|year=2001|pages=693–801}} </ref> <ref> {{cite journal|author=Barder O, Kremer M, Williams H|url=http://www.bepress.com/ev/vol3/iss3/art1 |title=Advance Market Commitments: A Policy to Stimulate Investment in Vaccines for Neglected Diseases|journal=The Economists' Voice|volume=3|year=2006|issue=3|doi=10.2202/1553-3832.1144}} </ref> Flere grupper deltager i forskningen, bl.a. [[Stop TB Partnership]], <ref> {{cite book|last=Economic|first=Department of|title=Achieving the global public health agenda : dialogues at the Economic and Social Council|year=2009|publisher=United Nations|location=New York|isbn=978-92-1-104596-3|pages=103|url=http://books.google.ca/books?id=VeF9dv74C4MC&pg=PA103|coauthors=Affairs, Social}} </ref> South African Tuberculosis Vaccine Initiative og [[Aeras Global TB Vaccine Foundation]]. <ref> {{cite book|last=Jong|first=[edited by] Jane N. Zuckerman, Elaine C.|title=Travelers' vaccines|year=2010|publisher=People's Medical Pub. House|location=Shelton, CT|isbn=978-1-60795-045-5|pages=319|url=http://books.google.ca/books?id=BKRpWFEy66wC&pg=PA319|edition=2nd ed.}} </ref> Aeras Global TB Vaccine Foundation modtog en gave på over 280 million US dollar fra [[Bill and Melinda Gates Foundation]] til at udvikle og få godkendt en forbedret vaccine mod tuberkulose, der kan bruges i hårdt belastede lande. <ref> {{Cite web|last=Bill and Melinda Gates Foundation Announcement|title=Gates Foundation Commits $82.9 Million to Develop New Tuberculosis Vaccines|date=2004-02-12| url=http://www.globalhealth.org/news/article/4134}} </ref> <ref> {{Cite web|last=Nightingale|first=Katherine|title=Gates foundation gives US$280 million to fight TB|date=2007-09-19|url=http://www.scidev.net/en/news/gates-foundation-gives-us280-million-to-fight-tb.html}} </ref>
105.886

redigeringer